Nanotech bill
This article was originally published in The Gray Sheet
Executive Summary
The Nanotechnology Safety Act of 2010, introduced Jan. 21 by Sens. Mark Pryor, D-Ariz., and Benjamin Cardin, D-Md., would establish a program within FDA "to assess the health and safety implications of nanotechnology in everyday products and develop best practices for companies who employ nanotechnology," according to Pryor. The program would be carried out at FDA's National Center for Toxicology Research in Jefferson, Ariz., and at FDA headquarters in White Oak, Md. Nanotechnology "has hundreds of promising applications," Pryor said. "As these products are developed and used, we must understand any potential risks to human health, safety or the environment.